Johnson & Johnson Tops Q4 EPS Forecasts

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate. Although sales surged in the Innovative Medicine ...